ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Basilea Pharmaceutica has licensed its antifungal agent isavuconazole, now in Phase III studies, to Japan’s Astellas Pharma. The Swiss firm will receive about $70 million up front and as much as $440 million in milestone payments. The partners will jointly develop the drug, and Astellas will cover commercialization costs. Separately, Basilea is regaining rights to the antibiotic ceftobiprole, licensed in 2005 to the Johnson & Johnson company Cilag. U.S. and European regulators rejected applications for the drug’s approval, questioning the reliability of data from J&J-run trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter